Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01843374 · OUTCOME

Disease Control Rate by Treatment Arm

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma · Source last updated 2026-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage
Interval / dispersion
95% Confidence Interval
Time frame
Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.

What was measured

Disease control rate (DCR) is defined as the proportion of participants with best response of complete response (CR), partial response (PR), or stable disease (SD) of ≥ 12 weeks duration

Analysis population: ITT population

Groups in this outcome

TREMELIMUMAB

Tremelimumab 10mg/kg

PLACEBO

Placebo.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TREMELIMUMAB382
PLACEBO189

Reported measurements

Source class 1
Values in Percentage · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
TREMELIMUMAB21.7Not reported16.028.3Not reported
PLACEBO27.7Not reported23.332.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        16.0
        upper Limit
        28.3
        value
        21.7
      2. group Id
        OG001
        lower Limit
        23.3
        upper Limit
        32.5
        value
        27.7
denom Units Selected
Participants
denoms
  1. counts
    1. group Id
      OG000
      value
      382
    2. group Id
      OG001
      value
      189
    units
    Participants
description
Disease control rate (DCR) is defined as the proportion of participants with best response of complete response (CR), partial response (PR), or stable disease (SD) of ≥ 12 weeks duration
dispersion Type
95% Confidence Interval
groups
  1. description
    Tremelimumab 10mg/kg
    id
    OG000
    title
    TREMELIMUMAB
  2. description
    Placebo.
    id
    OG001
    title
    PLACEBO
param Type
NUMBER
population Description
ITT population
reporting Status
POSTED
time Frame
Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years.
title
Disease Control Rate by Treatment Arm
type
SECONDARY
type Units Analyzed
Participants
unit Of Measure
Percentage

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice